PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1
Journal for ImmunoTherapy of Cancer · 2023
DOI: 10.1136/jitc-2023-006833 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Giuseppe Lo Russo und 35 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp and Dohme.
Abstract (Originalsprache)
Background Chemoimmunotherapy represents the standard of care for patients with advanced non-small cell lung cancer (NSCLC) and programmed death-ligand 1 (PD-L1)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy.
- Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milano, Lombardia, Italy.
- Thoracic Oncology Program, Section of Hematology/Oncology, University of Chicago Department of Medicine, Chicago, Illinois, USA.
- Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Milano, Lombardia, Italy.
- Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy.
ORCID-Profile: Arsela Prelaj
Förderung
- Merck Sharp and Dohme
Zitieren
APA
Lo Russo, G., Prelaj, A., Dolezal, J., Beninato, T., Agnelli, L., Triulzi, T., Fabbri, A., Lorenzini, D., Ferrara, R., Brambilla, M., Occhipinti, M., Mazzeo, L., Provenzano, L., Spagnoletti, A., Viscardi, G., Sgambelluri, F., Brich, S., Miskovic, V., Pedrocchi, A. L. G., …, & Garassino, M. C. (2023). PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-006833
Vancouver
Lo Russo G, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, et al. PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2023-006833
BibTeX
@article{LoRusso2023,
author = {Lo Russo, Giuseppe and Prelaj, Arsela and Dolezal, James and Beninato, Teresa and Agnelli, Luca and Triulzi, Tiziana and Fabbri, Alessandra and Lorenzini, Daniele and Ferrara, Roberto and Brambilla, Marta and Occhipinti, Mario and Mazzeo, Laura and Provenzano, Leonardo and Spagnoletti, Andrea and Viscardi, Giuseppe and Sgambelluri, Francesco and Brich, Silvia and Miskovic, Vanja and Pedrocchi, Alessandra Laura Giulia and Trovo', Francesco and Manglaviti, Sara and Giani, Claudia and Ambrosini, Paolo and Leporati, Rita and Franza, Andrea and McCulloch, John and Torelli, Tommaso and Anichini, Andrea and Mortarini, Roberta and Trinchieri, Giorgio and Pruneri, Giancarlo and Torri, Valter and De Braud, Filippo and Proto, Claudia and Ganzinelli, Monica and Garassino, Marina Chiara},
title = {PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
doi = {10.1136/jitc-2023-006833}
}
EUVIMED